Trial · NCT02278341
Results by group386
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 386
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change From Baseline (BL) to the Average Hemoglobin (Hb) in Weeks 28-36 Without Rescue Therapy [EU (EMA)] | Roxadustat | 0.428 | 95% Confidence Interval 0.350 to 0.506 | g/dL | |
| Change From Baseline (BL) to the Average Hemoglobin (Hb) in Weeks 28-36 Without Rescue Therapy [EU (EMA)] | ESA (Erythropoiesis-Stimulating Agent) | 0.193 | 95% Confidence Interval 0.117 to 0.268 | g/dL | |
| Change From BL to the Average Hb in Weeks 28 to 52 Regardless of Rescue Therapy [US (FDA)] | Roxadustat | 0.363 | 95% Confidence Interval 0.288 to 0.438 | g/dL | |
| Change From BL to the Average Hb in Weeks 28 to 52 Regardless of Rescue Therapy [US (FDA)] | ESA (Erythropoiesis-Stimulating Agent) | 0.192 | 95% Confidence Interval 0.121 to 0.262 | g/dL | |
| Percentage of Participants With Hb Response During Weeks 28 to 36 | Roxadustat | 84.2 | 95% Confidence Interval 80.2 to 87.7 | Percentage of participants | |
| Percentage of Participants With Hb Response During Weeks 28 to 36 | ESA (Erythropoiesis-Stimulating Agent) | 82.4 | 95% Confidence Interval 78.3 to 86.0 | Percentage of participants | |
| Change From BL in Low Density Lipoprotein Cholesterol (LDL-C) to the Average LDL-C of Weeks 12 to 28 | Roxadustat | -0.459 | 95% Confidence Interval -0.517 to -0.401 | mmol/L | |
| Change From BL in Low Density Lipoprotein Cholesterol (LDL-C) to the Average LDL-C of Weeks 12 to 28 | ESA (Erythropoiesis-Stimulating Agent) | -0.082 | 95% Confidence Interval -0.138 to -0.026 | mmol/L | |
| Mean Monthly Intravenous (IV) Iron Use | Roxadustat | 21.6 | 95% Confidence Interval 14.0 to 29.3 | mg per month | |
| Mean Monthly Intravenous (IV) Iron Use | ESA (Erythropoiesis-Stimulating Agent) | 53.5 | 95% Confidence Interval 46.0 to 61.1 | mg per month | |
| Change From BL in Short Form-36 (SF-36) Health Survey Physical Functioning (PF) Sub-score to the Average of Weeks 12 to 28 | Roxadustat | 0.050 | 95% Confidence Interval -0.640 to 0.740 | Units on a scale | |
| Change From BL in Short Form-36 (SF-36) Health Survey Physical Functioning (PF) Sub-score to the Average of Weeks 12 to 28 | ESA (Erythropoiesis-Stimulating Agent) | -0.155 | 95% Confidence Interval -0.825 to 0.514 | Units on a scale | |
| Change From BL in SF-36 Vitality (VT) Sub-score to the Average of Weeks 12 to 28 | Roxadustat | 0.460 | 95% Confidence Interval -0.329 to 1.249 | Units on a scale | |
| Change From BL in SF-36 Vitality (VT) Sub-score to the Average of Weeks 12 to 28 | ESA (Erythropoiesis-Stimulating Agent) | -0.396 | 95% Confidence Interval -1.165 to 0.373 | Units on a scale | |
| Change From BL in Mean Arterial Pressure (MAP) to the Average of Weeks 20 to 28 | Roxadustat | -0.969 | 95% Confidence Interval -1.838 to -0.099 | mmHg | |
| Change From BL in Mean Arterial Pressure (MAP) to the Average of Weeks 20 to 28 | ESA (Erythropoiesis-Stimulating Agent) | -0.120 | 95% Confidence Interval -0.972 to 0.732 | mmHg | |
| Time to First Occurrence of an Increase in Blood Pressure | Roxadustat | Week 12 | 11.7 | 95% Confidence Interval 8.5 to 14.9 | Percentage of participants |
| Time to First Occurrence of an Increase in Blood Pressure | ESA (Erythropoiesis-Stimulating Agent) | Week 12 | 11.1 | 95% Confidence Interval 8.0 to 14.2 | Percentage of participants |
| Time to First Occurrence of an Increase in Blood Pressure | Roxadustat | Week 24 | 15.9 | 95% Confidence Interval 12.2 to 19.6 | Percentage of participants |
| Time to First Occurrence of an Increase in Blood Pressure | ESA (Erythropoiesis-Stimulating Agent) | Week 24 | 15.4 | 95% Confidence Interval 11.9 to 19.0 | Percentage of participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02278341/results